as 01-17-2025 4:00pm EST
Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.
Founded: | 1984 | Country: | United States |
Employees: | N/A | City: | ST LOUIS |
Market Cap: | 29.0B | IPO Year: | 2001 |
Target Price: | $80.86 | AVG Volume (30 days): | 5.5M |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 5.75 | EPS Growth: | 29.81 |
52 Week Low/High: | $55.03 - $81.42 | Next Earning Date: | 02-04-2025 |
Revenue: | $146,204,000,000 | Revenue Growth: | 4.91% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 4.43% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Greco Thomas | CNC | Director | Dec 18 '24 | Buy | $59.75 | 17,000 | $1,015,750.00 | 19,309 | |
BLUME JESSICA L. | CNC | Director | Dec 16 '24 | Buy | $59.48 | 250 | $14,870.00 | 250 | |
Dallas H James | CNC | Director | Dec 16 '24 | Buy | $59.01 | 1,693 | $99,903.93 | 1,693 | |
Samuels Theodore R. II | CNC | Director | Dec 13 '24 | Buy | $58.86 | 5,000 | $294,300.00 | 23,000 | |
LONDON SARAH | CNC | Chief Executive Officer | Nov 8 '24 | Buy | $60.80 | 4,117 | $250,313.60 | 667,229 |
CNC Breaking Stock News: Dive into CNC Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Insider Monkey
3 days ago
PR Newswire
3 days ago
PR Newswire
4 days ago
Insider Monkey
4 days ago
PR Newswire
5 days ago
Zacks
5 days ago
Zacks
5 days ago
The information presented on this page, "CNC Centene Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.